Cargando…

Effect of Sleeve Gastrectomy on Morbid Obesity with Type 1 Diabetes Mellitus; Case Series, Literature Review and Meta-Analysis

PURPOSE: The aim of this study was to report our experiences of sleeve gastrectomy (SG) in obese patients with type 1 diabetes mellitus (T1DM) and to assess its metabolic outcomes through a review of the literature and a meta-analysis. MATERIALS AND METHODS: We conducted a retrospective review of th...

Descripción completa

Detalles Bibliográficos
Autores principales: Jin, Hana, Kim, Sang Hyun, Chung, Yoona, Park, Dae Geun, Kim, Yong Jin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Korean Society for Metabolic and Bariatric Surgery 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9847656/
https://www.ncbi.nlm.nih.gov/pubmed/36688117
http://dx.doi.org/10.17476/jmbs.2020.9.2.52
Descripción
Sumario:PURPOSE: The aim of this study was to report our experiences of sleeve gastrectomy (SG) in obese patients with type 1 diabetes mellitus (T1DM) and to assess its metabolic outcomes through a review of the literature and a meta-analysis. MATERIALS AND METHODS: We conducted a retrospective review of the electronic medical records of all patients who underwent bariatric surgery between January 2008 and February 2019 at a single institution. A literature search was performed using PubMed, Cochrane library, and Embase, and a meta-analysis for each direct comparison between pre- and postoperative groups was performed using the random effects DerSimonian–Laird method. RESULTS: We identified three obese patients with T1DM who underwent SG. The baseline body mass index (BMI), HbA1c, and total daily insulin dose was 40.8 (37–47.4) kg/m(2), 7.1% (6%–7.7%), and 92.3 (54–113) units, respectively. After surgery, the BMI and total daily insulin dose reduced to 32.2 (30.2-37.6) kg/m(2) and 22.3 (12-40) units, respectively. However, the HbA1c increased to 7.8% (5.4%-10.8%). In the meta-analysis, the weighted mean reduction in BMI, HbA1c, and total daily insulin dose were 10.69 kg/m(2) (95% CI 7.01-14.37, P<0.00001, I(2)=0%), 0.3% (95% CI −0.10–0.71, P=0.1447, I(2)=0%), and 58.52 units (95% CI 15.96-101.08, P=0.07, I(2)=0%), respectively. CONCLUSION: SG showed excellent weight-reducing effects during a short follow-up period in obese patients with T1DM and improved the glycemic control by reducing insulin requirement.